Pinealon
Biologically active food supplement PINEALON® is a peptide complex containing amino acids: glutamic
acid, aspartic acid, and arginine, which has a normalizing effect on brain tissue.
PINEALON® is available in tablets or capsules with an active substance content of 0.100 mg.
Experimental studies have shown that PINEALON® has a tissue-specific effect on brain cells: it regu-
lates metabolic processes in brain cells, increases the reserve capacity of the brain, exerts a beneficial
impact on the body’s adaptation processes in extreme conditions, has antioxidant properties, and
regulates the processes of peroxidation in the cerebral cortex of the brain. This allows us to assume
the effectiveness of using PINEALON® to restore the functions of the central nervous system in the
case of disorders of various origins.
Treatment of central nervous system diseases is of particular relevance because they lead to social
adaptation disorder and disability of patients (2).
Currently, the treatment of patients with diseases of the central nervous system, given the pathoge-
netic mechanisms, is carried out using the following traditional therapeutic agents of various action
types (1, 3):
- Influence on metabolism and integrative functions of the brain – (cerebrolysin, piracetam, enceph-
alolysate);
- Normalization of cerebral and systemic circulation – (stugeron, cavinton);
- Relief of psychopathological symptoms – (meridin, amitriptyline);
- Correction of changes in the bioelectric activity of the brain – (phenobarbital, Convulex);
- Impact on liquorodynamic disturbances – (verospiron, furosemide);
- Prevention and inhibition of the development of adhesions – (aloe, lidase);
- Correction of immunopathological reactions – (levamisole, tavegil).
Clinical trials of PINEALON® took place from November 2005 to February 2006 at the Medical Center
of the Saint Petersburg Institute of Bioregulation and Gerontology of the Northwest Branch of the
Russian Academy of Medical Sciences.
In total, 42 patients with various diseases of the central nervous system participated: long-term con-
sequences of craniocerebral injury (the duration of the injuries varied between 1 to 10 years), post-
stroke conditions, vascular encephalopathies, decreased mental performance, memory, attention. You
can see the distribution of patients by nosological forms, sex, and age in Table 1.
In addition to conventional treatment, patients in the primary group received PINEALON® 1-2 capsules
2-3 times a day before meals for 10-20 days, depending on the severity of the pathological process.
The control group consisted of 32 similar patients who received only conventional treatment.
All patients have been taking symptomatic and pathogenetic drugs. Taking these drugs has resulted
in a short-term therapeutic effect, which required an increase in the dose per treatment course and
their prolonged use.
Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.
Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.